Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression

Rachana Patel, Meiling Gao, Imran Ahmad, Janis Fleming, Lukram B. Singh, Taranjit Singh Rai, Arthur B. McKie, Morag Seywright, Robert J. Barnetson, Joanne Edwards, Owen J. Sansom, Hing Y. Leung

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Concurrent activation of RAS/ERK and PI3K/AKT pathways is implicated in prostate cancer progression. The negative regulators of these pathways, including sprouty2 (SPRY2), protein phosphatase 2A (PP2A), and phosphatase and tensin homolog (PTEN), are commonly inactivated in prostate cancer. The molecular basis of cooperation between these genetic alterations is unknown. Here, we show that SPRY2 deficiency alone triggers activation of AKT and ERK, but this is insufficient to drive tumorigenesis. In addition to AKT and ERK activation, SPRY2 loss also activates a PP2A-dependent tumor suppressor checkpoint. Mechanistically, the PP2A-mediated growth arrest depends on GSK3β and is ultimately mediated by nuclear PTEN. In murine prostate cancer models, Pten haploinsufficiency synergized with Spry2 deficiency to drive tumorigenesis, including metastasis. Together, these results show that loss of Pten cooperates with Spry2 deficiency by bypassing a novel tumor suppressor checkpoint. Furthermore, loss of SPRY2 expression correlates strongly with loss of PTEN and/or PP2A subunits in human prostate cancer. This underlines the cooperation between SPRY2 deficiency and PTEN or PP2A inactivation in promoting tumorigenesis. Overall, we propose SPRY2, PTEN, and PP2A status as an important determinant of prostate cancer progression. Characterization of this trio may facilitate patient stratification for targeted therapies and chemopreventive interventions.

LanguageEnglish
Pages1157-1175
Number of pages19
JournalJournal of Clinical Investigation
Volume123
Issue number3
DOIs
Publication statusPublished - 1 Mar 2013

Fingerprint

Protein Phosphatase 2
Phosphoric Monoester Hydrolases
Prostatic Neoplasms
Carcinogenesis
Haploinsufficiency
Phosphatidylinositol 3-Kinases
Tensins
Neoplasms
Neoplasm Metastasis
Growth

Cite this

Patel, R., Gao, M., Ahmad, I., Fleming, J., Singh, L. B., Rai, T. S., ... Leung, H. Y. (2013). Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression. Journal of Clinical Investigation, 123(3), 1157-1175. https://doi.org/10.1172/JCI63672
Patel, Rachana ; Gao, Meiling ; Ahmad, Imran ; Fleming, Janis ; Singh, Lukram B. ; Rai, Taranjit Singh ; McKie, Arthur B. ; Seywright, Morag ; Barnetson, Robert J. ; Edwards, Joanne ; Sansom, Owen J. ; Leung, Hing Y. / Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression. In: Journal of Clinical Investigation. 2013 ; Vol. 123, No. 3. pp. 1157-1175.
@article{ea074f04b17b459dad26554861a95c4c,
title = "Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression",
abstract = "Concurrent activation of RAS/ERK and PI3K/AKT pathways is implicated in prostate cancer progression. The negative regulators of these pathways, including sprouty2 (SPRY2), protein phosphatase 2A (PP2A), and phosphatase and tensin homolog (PTEN), are commonly inactivated in prostate cancer. The molecular basis of cooperation between these genetic alterations is unknown. Here, we show that SPRY2 deficiency alone triggers activation of AKT and ERK, but this is insufficient to drive tumorigenesis. In addition to AKT and ERK activation, SPRY2 loss also activates a PP2A-dependent tumor suppressor checkpoint. Mechanistically, the PP2A-mediated growth arrest depends on GSK3β and is ultimately mediated by nuclear PTEN. In murine prostate cancer models, Pten haploinsufficiency synergized with Spry2 deficiency to drive tumorigenesis, including metastasis. Together, these results show that loss of Pten cooperates with Spry2 deficiency by bypassing a novel tumor suppressor checkpoint. Furthermore, loss of SPRY2 expression correlates strongly with loss of PTEN and/or PP2A subunits in human prostate cancer. This underlines the cooperation between SPRY2 deficiency and PTEN or PP2A inactivation in promoting tumorigenesis. Overall, we propose SPRY2, PTEN, and PP2A status as an important determinant of prostate cancer progression. Characterization of this trio may facilitate patient stratification for targeted therapies and chemopreventive interventions.",
author = "Rachana Patel and Meiling Gao and Imran Ahmad and Janis Fleming and Singh, {Lukram B.} and Rai, {Taranjit Singh} and McKie, {Arthur B.} and Morag Seywright and Barnetson, {Robert J.} and Joanne Edwards and Sansom, {Owen J.} and Leung, {Hing Y.}",
year = "2013",
month = "3",
day = "1",
doi = "10.1172/JCI63672",
language = "English",
volume = "123",
pages = "1157--1175",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
number = "3",

}

Patel, R, Gao, M, Ahmad, I, Fleming, J, Singh, LB, Rai, TS, McKie, AB, Seywright, M, Barnetson, RJ, Edwards, J, Sansom, OJ & Leung, HY 2013, 'Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression', Journal of Clinical Investigation, vol. 123, no. 3, pp. 1157-1175. https://doi.org/10.1172/JCI63672

Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression. / Patel, Rachana; Gao, Meiling; Ahmad, Imran; Fleming, Janis; Singh, Lukram B.; Rai, Taranjit Singh; McKie, Arthur B.; Seywright, Morag; Barnetson, Robert J.; Edwards, Joanne; Sansom, Owen J.; Leung, Hing Y.

In: Journal of Clinical Investigation, Vol. 123, No. 3, 01.03.2013, p. 1157-1175.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression

AU - Patel, Rachana

AU - Gao, Meiling

AU - Ahmad, Imran

AU - Fleming, Janis

AU - Singh, Lukram B.

AU - Rai, Taranjit Singh

AU - McKie, Arthur B.

AU - Seywright, Morag

AU - Barnetson, Robert J.

AU - Edwards, Joanne

AU - Sansom, Owen J.

AU - Leung, Hing Y.

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Concurrent activation of RAS/ERK and PI3K/AKT pathways is implicated in prostate cancer progression. The negative regulators of these pathways, including sprouty2 (SPRY2), protein phosphatase 2A (PP2A), and phosphatase and tensin homolog (PTEN), are commonly inactivated in prostate cancer. The molecular basis of cooperation between these genetic alterations is unknown. Here, we show that SPRY2 deficiency alone triggers activation of AKT and ERK, but this is insufficient to drive tumorigenesis. In addition to AKT and ERK activation, SPRY2 loss also activates a PP2A-dependent tumor suppressor checkpoint. Mechanistically, the PP2A-mediated growth arrest depends on GSK3β and is ultimately mediated by nuclear PTEN. In murine prostate cancer models, Pten haploinsufficiency synergized with Spry2 deficiency to drive tumorigenesis, including metastasis. Together, these results show that loss of Pten cooperates with Spry2 deficiency by bypassing a novel tumor suppressor checkpoint. Furthermore, loss of SPRY2 expression correlates strongly with loss of PTEN and/or PP2A subunits in human prostate cancer. This underlines the cooperation between SPRY2 deficiency and PTEN or PP2A inactivation in promoting tumorigenesis. Overall, we propose SPRY2, PTEN, and PP2A status as an important determinant of prostate cancer progression. Characterization of this trio may facilitate patient stratification for targeted therapies and chemopreventive interventions.

AB - Concurrent activation of RAS/ERK and PI3K/AKT pathways is implicated in prostate cancer progression. The negative regulators of these pathways, including sprouty2 (SPRY2), protein phosphatase 2A (PP2A), and phosphatase and tensin homolog (PTEN), are commonly inactivated in prostate cancer. The molecular basis of cooperation between these genetic alterations is unknown. Here, we show that SPRY2 deficiency alone triggers activation of AKT and ERK, but this is insufficient to drive tumorigenesis. In addition to AKT and ERK activation, SPRY2 loss also activates a PP2A-dependent tumor suppressor checkpoint. Mechanistically, the PP2A-mediated growth arrest depends on GSK3β and is ultimately mediated by nuclear PTEN. In murine prostate cancer models, Pten haploinsufficiency synergized with Spry2 deficiency to drive tumorigenesis, including metastasis. Together, these results show that loss of Pten cooperates with Spry2 deficiency by bypassing a novel tumor suppressor checkpoint. Furthermore, loss of SPRY2 expression correlates strongly with loss of PTEN and/or PP2A subunits in human prostate cancer. This underlines the cooperation between SPRY2 deficiency and PTEN or PP2A inactivation in promoting tumorigenesis. Overall, we propose SPRY2, PTEN, and PP2A status as an important determinant of prostate cancer progression. Characterization of this trio may facilitate patient stratification for targeted therapies and chemopreventive interventions.

UR - http://www.scopus.com/inward/record.url?scp=84874599503&partnerID=8YFLogxK

U2 - 10.1172/JCI63672

DO - 10.1172/JCI63672

M3 - Article

VL - 123

SP - 1157

EP - 1175

JO - Journal of Clinical Investigation

T2 - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 3

ER -